Skip to main content
SYRA
OTC Trade & Services

Syra Health Amends 10-K to Detail Executive Compensation, Ownership, and Governance

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$0.47
Mkt Cap
$5.611M
52W Low
$0.031
52W High
$0.7
Market data snapshot near publication time

summarizeSummary

Syra Health Corp filed an amended 10-K to include previously omitted Part III information, detailing executive compensation, director changes, and beneficial ownership, which are important for investor understanding of the micro-cap company's leadership and capital structure.


check_boxKey Events

  • New CEO Compensation Detailed

    Gregory R. Alexander, appointed CEO effective January 5, 2026, will receive an annual base salary of $251,000, 110,537 restricted stock units, 257,920 stock options, and 368,458 performance stock units. These equity awards represent a notable potential dilution for the micro-cap company.

  • Executive Departures Clarified

    The former CEO, Deepika Vuppalanchi, was terminated for cause on June 13, 2025. Additionally, former President Sandeep Allam passed away on January 15, 2025. These details provide clarity on significant leadership changes.

  • Significant Insider Ownership Disclosed

    As of December 31, 2025, former President Sandeep Allam held 20.65% of Class A common stock, and former CEO Deepika Vuppalanchi held 41.7% of Class B voting power. Priya Prasad, CFO/COO, holds 13.7% of total voting power.

  • Ongoing Related Party Transactions

    The company continues to engage in related party transactions for office lease, IT services, and recruitment/HR services with entities beneficially owned by principal owners and management, totaling significant expenses in 2025.


auto_awesomeAnalysis

This 10-K/A filing provides crucial details on executive compensation, director information, and beneficial ownership that were omitted from the original 10-K. For a micro-cap company facing going concern issues, understanding leadership incentives and potential dilution is vital. The filing details the new CEO's significant compensation package, including equity awards that represent a notable potential dilution. It also clarifies the circumstances of previous executive departures and ongoing related party transactions, offering a more complete picture of the company's internal structure and financial commitments.

At the time of this filing, SYRA was trading at $0.47 on OTC in the Trade & Services sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.03 to $0.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SYRA - Latest Insights

SYRA
May 07, 2026, 8:16 AM EDT
Filing Type: 8-K
Importance Score:
9
SYRA
May 07, 2026, 7:55 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
SYRA
Apr 24, 2026, 9:55 PM EDT
Filing Type: 10-K/A
Importance Score:
7
SYRA
Apr 02, 2026, 5:28 PM EDT
Source: Reuters
Importance Score:
7
SYRA
Mar 12, 2026, 5:25 PM EDT
Filing Type: 10-K
Importance Score:
8
SYRA
Mar 12, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
8
SYRA
Mar 12, 2026, 7:55 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
SYRA
Jan 16, 2026, 1:56 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
7